HK Stock MarketDetailed Quotes

02269 WUXI BIO

28.600 -0.750-2.56%
Not Open 12/11 16:08 CST
  • 5D
  • 1D
  • 1W
  • 1M
  • 1Q
  • 1Y

About WUXI BIO Company

The Group is the world's leading open biopharmaceutical technology platform company, providing end-to-end solutions for the discovery, development and production of biopharmaceuticals. Biopharmaceuticals are a subclassification of pharmaceuticals that have revolutionized the treatment of diseases in many major treatment fields around the world. The Group's end-to-end service platform enables it to provide services covering the entire biopharmaceutical development process and to provide customers with customized solutions according to their individual service requirements at any stage of the biopharmaceutical development process. The biopharmaceutical development process generally covers five stages: (i) drug discovery, (ii) preclinical development, (iii) early (phase I and II) clinical development, (iv) late stage (phase III) clinical development, and (v) commercial production. The services required for the biopharmaceutical development process can be divided into two categories: (1) pre-IND services, which include services provided in the first two stages of the biopharmaceutical development process, and (2) post-IND services, which include services provided in the remaining three stages of the biopharmaceutical development process. The Group's business model is based on its “follow the molecule” and “win the molecule” strategy. Customer demand for the Group's services will generally increase as their biopharmaceuticals advance through the biopharmaceutical development process and eventually commercialize production. As a result, the Group's revenue from each integrated project usually also increases as the project progresses.